依普利酮是什么呢？

It is a new generation of selective aldosterone antagonist, developed by Pfizer, and first launched in the United States in 2002 under the trade name Inspra. Eplerenone is indicated for the treatment of congestive heart failure after acute myocardial infarction and for the treatment of hypertension. Eplerenone is a good medicine for the treatment of hypertension, and can also be used as a medicine for myocardial ischemia and chronic myocardial insufficiency. It can protect the liver, heart disease, and kidneys without damaging the organs, and can promote urination without losing potassium.

Aldosterone is an important component present in the renin-angiotensin-aldosterone system (RAAS) and plays an important role in the regulation of the human cardiovascular system.

Eplerenone selectively acts on aldosterone receptors and is highly selective for mineralocorticoid receptors, but has less effect on androgen and progesterone receptors. Its affinity for mineralocorticoids is 15 to 20 times that of spironolactone, while its affinity for androgen and progesterone receptors is 500 times smaller than that of spironolactone, so sex hormone-related adverse reactions are less likely to occur.

The recommended dose for the treatment of adults with congestive heart failure is an initial dose of 25 mg orally once daily; gradually increase to the target dose within 4 weeks as tolerated by the patient. Target dose: 50 mg orally once daily.

Common dosages for the treatment of hypertension in adults: Eplerenone can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg orally once daily; Maintenance dose: 50 mg orally once or twice daily; Maximum dose: 100 mg/day. Obvious antihypertensive effects appear within four weeks of taking the drug. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

With the continuous progress of research, the scope of clinical application is constantly being expanded, and its status in the field of cardiovascular disease treatment is also constantly being improved.